PB-201

Cat. No. M31408

Size	Price	Availability	Quantity

Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation

Purity: >99.0%
COA
MSDS

Product Information

Biological Activity

PB-201 is a glucokinase activator (GKA) that can be used in studies related to type 2 diabetes.

Chemical Information

Storage

Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month

Conversion of different model animals based on BSA (PMID: 27057123)

Species	Mouse	Rat	Rabbit	Guinea pig	Hamster	Dog
Weight (kg)	0.02	0.15	1.8	0.4	0.08	10
Body Surface Area (m²)	0.007	0.025	0.15	0.05	0.02	0.5
K_m factor	3	6	12	8	5	20

Animal A (mg/kg) = Animal B (mg/kg) multiplied by	Animal B K_m
	Animal A K_m

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the K_m factor for a mouse and then divide by the K_m factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Miao Zhang, et al. CPT Pharmacometrics Syst Pharmacol. Development of a PBPK model to quantitatively understand absorption and disposition mechanism and support future clinical trials for PB-201

[2] Ying Du, et al. Diabetes Obes Metab. A multicentre, randomized, double-blind, parallel, active- and placebo-controlled Phase 3 clinical study of the glucokinase activator PB-201 in treatment-naive patients with type 2 diabetes mellitus: A study protocol

[3] Yixin Ren, et al. J Enzyme Inhib Med Chem. Glucokinase as an emerging anti-diabetes target and recent progress in the development of its agonists

[4] Dongyang Liu, et al. EClinicalMedicine. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator PB-201 and its effects on the glucose excursion profile in drug-naïve Chinese patients with type 2 diabetes: a randomised controlled, crossover, single-centre phase 䲧癐Ỵ癑

[5] F Tárkányi, et al. Appl Radiat Isot. Investigation of activation cross-sections of proton induced nuclear reactions on natTl up to 42MeV: review, new data and evaluation

Related Glucokinase (GK) Products
AZD1092 AZD1092 is an orally active glucokinase (GK) activator with an EC50 value of 0.03 μM.
GKM-001 GKM-001 is a glucokinase (GK) activator that can be used in studies related to type 2 diabetes.
TMG-123 TMG-123 is a glucokinase (GK) activator that can be used in studies related to type 2 diabetes.
MK-0941 free base MK-0941 free base is an orally active glucokinase activator, with EC50s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 free base exhibits strong glucose-lowering activity and is a potential therapeutic agent for treatment of type 2 diabetes.
AMG-1694 AMG-1694 is a potent glucokinase–glucokinase regulatory protein (GK-GKRP) disruptors and promotes the dissociation of the GK-GKRP complex with an IC50 of 7 nM, indirectly increasing GK enzymatic activity. AMG-1694 potently reverses the inhibitory effect of GKRP on GK activity and promotes GK translocation. AMG-1694 normalizes blood glucose levels in several rodent models of diabetes and lowes blood glucose restricted to diabetic and not normoglycaemic animals.

Catalog

By Signaling Pathways

By Product Type

Signaling Pathways

PB-201

Quality Control & Documentation

Biological Activity

Chemical Information

Conversion of different model animals based on BSA (PMID: 27057123)

References

Get to Know Us

Customer Support

Resources

Contact Us